GenScript Biotech Corporation

GenScript Biotech Corporation is a global biotechnology company dedicated to accelerating innovation in biotech and healthcare by providing researchers and companies with essential building blocks for groundbreaking treatments and products. Founded in 2002 in New Jersey, the company operates with a mission to "Make People and Nature Healthier Through Biotechnology." While its corporate headquarters are located in Nanjing, China, it maintains a significant operational presence, including a key site in Piscataway, New Jersey, USA.

The company's operations are structured across four main segments: a CDMO (Contract Development and Manufacturing Organization) platform, a life-science services and products platform, an integrated cell therapy platform, and an industrial synthetic products platform. Key offerings from its life science services and products segment include DNA synthesis, oligonucleotide synthesis, peptide synthesis, protein production, antibody development, and various life-science equipment and consumables. GenScript also operates through notable subsidiaries such as Legend Biotech, which focuses on integrated cell therapy, ProBio, providing end-to-end CDMO services, and Bestzyme, specializing in synthetic biology for enzyme development across diverse industries.

Under the leadership of Rotating CEO Sherry Shao, GenScript has demonstrated strong financial performance, reporting significant revenue and profit growth in the first half of 2025. The company unveiled a new global brand identity, "Scripting Possibilities," in August 2025, reflecting its ambition to be a trusted partner in biotechnology. GenScript's commitment to responsible practices is underscored by an upgraded MSCI ESG rating to AA in August 2025, positioning it as a leader in sustainable biotech innovation. With a global footprint serving over 200,000 customers across more than 100 countries, GenScript maintains a strong market position as a pioneer in life sciences innovation.